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A B S T R A C T
Objectives: The overall reported burden of invasive pneumococcal disease (IPD) varies among countries
in Europe. This review describes the epidemiology and serotype distribution of IPD in European children
from studies published from 1990 to 2008.
Methods: Averages were derived from all studies from all countries that had available data.
Results: Before widespread immunization with 7-valent pneumococcal conjugate vaccine (PCV7), the
overall mean annual incidence of IPD in children aged<2 years was 44.4/100 000. Themean case fatality
rate for IPD was 3.5%, and resistant rates were approximately 23% for penicillin G (minimum inhibitory
concentration 2 mg/l), 41% for erythromycin, and 9% (5 years) for third-generation cephalosporins.
The most common serotypes causing IPD were 14, 6B, 19F, and 23F, all of which are included in PCV7.
Vaccine serotype coverage ranged from 37% to 100% for PCV7, withmean increases in coverage of 7% and
16% for investigational 10- and 13-valent pneumococcal conjugate vaccines, respectively. The most
common IPD isolates since PCV7 introduction in Belgium, France, Germany, Greece, Norway, Portugal,
Spain, and the UK were serotypes 1, 19A, 3, 6A, and 7F.
Conclusions: With routine effective use of PCV7, a general decline in IPD, antibiotic non-susceptibility,
and vaccine serotypes has been observed. The most common IPD isolates since PCV7 introduction are
serotypes 1, 19A, 3, 6A, and 7F, highlighting the need for inclusion of these serotypes in future vaccine
formulations.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Streptococcus pneumoniae is a major source of morbidity and
mortality worldwide. It is estimated by the World Health
Organization (WHO) that approximately 1 million children die
of pneumococcal disease every year, mostly in developing
countries.1,2 Pneumococcal infections are the leading cause of
death from a vaccine-preventable illness in children aged <5
years.3 Invasive diseases caused by pneumococci include menin-
gitis, bacteremia, and pneumonia with bacteremia and/or
empyema. Risk factors for invasive pneumococcal disease (IPD)
include age (with incidence being highest in young children aged
<2 years and the elderly aged >65 years), ethnicity, geographic* Corresponding author. Tel.: +1 484 865 3027; fax: +1 484 865 4199.
E-mail address: isaacmd@wyeth.com (D.J. Isaacman).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.05.010location, concomitant chronic illnesses, and attendance in day care
centers.1,4 The reported burden of disease varies by region in
Europe as demonstrated by the broad range of incidence of IPD and
of antibiotic resistance of S. pneumoniae in European children by
country.5,6 Under-reporting inﬂuences the variation of disease
incidence among countries, and hence has a major impact on the
perception of the burden of disease.7 Although 91 distinct
pneumococcal serotypes varying in capsular polysaccharide
structure have been described and categorized into 46 different
serogroups based on immunological cross-reactivity, not all are
known to cause disease.8–10 Data on serotype distribution and
disease incidence are essential for assessment of the potential
impact of pneumococcal conjugate vaccines (PCV).11 While this
review focuses on the incidence and serotypes of S. pneumoniae
causing IPD in young children, it also includes data on mortality,
general antibiotic resistance trends, special high-risk populations,
and indirect (herd) effects of conjugate vaccine use, whenses. Published by Elsevier Ltd. All rights reserved.
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literature on the burden of IPD on young children in Europe from
January 1990 to June 2008.
2. Methods
Data published from January 1990 through April 2008 were
identiﬁed using MEDLINE and EMBASE databases. There were no
language restrictions. Search terms included: invasive pneumo-
coccal disease, serotypes, Streptococcus pneumoniae, pneumococ-
cus, pneumococcal, and pneumococcal conjugate vaccine.
Additional data were identiﬁed by subsequent ad hoc searches
of Internet sources and reviews of the bibliographies of retrieved
manuscripts and abstracts from the proceedings of the Interna-
tional Symposium for Pneumococci and Pneumococcal Diseases
(ISPPD), Interscience Conference of Antimicrobial Agents and
Chemotherapy (ICAAC), Infectious Diseases Society of America
(IDSA), World Congress of Paediatric Infectious Diseases (WSPID),
Pediatric Academic Societies (PAS), and the European Society for
Paediatric Infectious Diseases (ESPID). Some of the material
identiﬁed through the subsequent ad hoc Internet searches and
reviews of the bibliographies of retrieved manuscripts and
abstracts of presentations at scientiﬁc congresses were published
after the April 2008 cut-off date for the initial database search.
2.1. Inclusion criteria
All studies that described serogrouping and/or serotyping of S.
pneumoniae isolates obtained from pediatric patients with IPD
were included in the review.We chose a limit of 18 years of age for
inclusion, even though ‘pediatric age’ was deﬁned in several ways
in the studies. Studies that included data on adult patients were
included only if serotype distribution between adults and children
were separated. More than one study per country was counted
when calculating the mean incidence of disease, serotype
distribution,mortality, and general antibiotic susceptibility trends.
All studies were weighted equally when averages were computed.
The deﬁnitions of ‘active’ and ‘passive’ were deﬁned by each
published study. In general, active studies were prospective,
population-based studies, which often contained both laboratory
and clinical information, whereas passive studies generally
consisted of retrospective laboratory reporting.
2.2. Exclusion criteria
Studies were not included in this review if adult and pediatric
serotype/serogroup distribution was not differentiated, the source
of the isolates was not speciﬁed, or serotypes/serogroups of non-
sterile isolates were not differentiated from sterile isolates.Figure 1. Pneumococcal serotypes included in the currently licensed 7-valent2.3. Vaccine formulations and calculation of potential serotype
coverage
Studies were organized by the timing of implementation of
national immunization programs with the currently licensed
heptavalent pneumococcal conjugate vaccine (PCV7; serotypes 4,
6B, 9 V, 14, 18C, 19F, and 23F) and the availability of data following
introduction.Where available, the percentage of serotype coverage
for PCV7 and for investigational 10-valent (PCV7 plus additional
serotypes 1, 5, and 7F) and 13-valent (PCV7 plus additional
serotypes 1, 3, 5, 6A/C, 7F, and 19A)12,13 PCVs were noted
(Figure 1). Serotype coverage calculationwas performedwhenever
possible, by using only the serotypes within the vaccine without
taking into account potential serogroup cross-protection as the
base case. When only serogroup data were available, the
calculations for PCV7 and investigational 10-valent PCV were
based on serogroups, thereby potentially over-estimating coverage
for these two vaccines.
2.4. Estimation of incidence of preventable disease
The burden of vaccine-preventable disease was calculated by
multiplying the proportion of severe disease caused by vaccine
serotypes by the total incidence of pneumococcal disease.1
2.5. Antimicrobial resistance
The percentages of pneumococcal isolates thatwere resistant to
penicillin, erythromycin, and speciﬁc third-generation cephalos-
porins were included, if available. Isolates were considered
‘resistant’ if they had at least intermediate resistance (i.e.,
penicillin G minimum inhibitory concentration (MIC) 0.12 mg/
l; erythromycin MIC 0.5 mg/l; ceftriaxone MIC 1 mg/l; cefotax-
ime MIC 1 mg/l; cefpodoxime MIC 1 mg/l).14 Since most of the
available data used the older Clinical and Laboratory Standards
Institute (CLSI) guidelines, we adhered to the penicillin G
breakpoints of MIC = 0.1–1 mg/l for intermediate and MIC
2 mg/l for resistant. The most recent CLSI guidelines have
deﬁned new resistance breakpoints to parenteral penicillin G for
pneumococcal meningitis strains as MIC 0.06 mg/l (susceptible)
and 0.1 mg/l (resistant), and non-meningeal (including pneu-
mococcal pneumonia) strains as MIC 2 mg/l (susceptible),
MIC = 4 mg/l (intermediate), and MIC 8 mg/l (resistant).14,15
Mean resistance was determined by averaging available data
from each study for each antibiotic.
Where data were available, comparisons of epidemiology
(incidence of IPD, estimated incidence of preventable disease,
clinical manifestations, special/high-risk populations, and general
antibiotic resistance trends) and serotype distribution for IPDwereand investigational 10- and 13-valent pneumococcal conjugate vaccines.
Figure 2. Annual incidence of pneumococcal meningitis and related 7-valent
pneumococcal conjugate vaccine (PCV7) coverage from active surveillance studies
by age group.
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European countries therewas a recommendation for vaccination of
‘at risk’ children up to 5 years of age.16 Therefore, there are not
clear data on vaccine uptake, and thus the inﬂuence of PCV7
immunization on serotype coverage is difﬁcult to estimate.
3. Results and discussion
3.1. Pre-national immunization program
3.1.1. Epidemiology
3.1.1.1. Incidence of IPD. Table 1 includes available data regarding
the annual incidence of IPD in this review of multiple studies in
European countries. The overall mean reported annual incidence
of IPD (cases/100 000) in children in Table 1 was 31.1, ranging
from 3.1 in Portugal17 to 110.2 in Spain.18 In children with
pneumococcal meningitis, the overall mean annual incidence
(cases/100 000) was 7.5, ranging from 0.7 in the UK19 to 22.0
in Spain.18 Studies performed in Austria,20Belgium,21 Denmark,22
Finland,23 Germany,24–27 Hungary,28 Italy,29 Norway,30 Portugal,17
Slovakia,31Spain,32–34 and the UK35,36 have estimated the incidence
of IPD from prospective/active surveillance studies, whereas the
incidence of IPD in other studies conducted in Denmark,37–39
the Netherlands,40 Norway,41 Poland,42 Slovenia,43 Spain,18,44–47
Sweden,48 and the UK19,49–53 were estimated from passive
surveillance analyses.
Among studies that reported using active surveillance, the
mean reported annual incidence of IPD was higher for children
aged <2 years (37.1; range 11.3–104.4) compared with those aged
<5 years (17.5; range 4.0–59.5) (Table 1). As expected, a greater
mean incidence of preventable disease would be predicted for
children aged <2 years (28.1; range 8.1–78.3) compared with
children aged <5 years (12.2; range 3.1–39.9). By country, the
incidence of IPD was elevated in Belgium and the Scandinavian
countries, and was lower in Austria, Germany, Italy, Hungary, and
Slovakia.
Among studies that reported using passive surveillance, the
mean reported annual incidence of IPDwas also higher for children
aged <2 years (51.7; range 17.2–93.5) compared with those aged
<5 years (39.0; range 22.8–56.2) (Table 1). A greater mean
incidence of preventable disease would again be predicted for
children aged <2 years (36.7; range 12.0–73.9) compared with
children aged <5 years (27.6; range 16.3–42.1). By country, the
incidence of IPD was elevated in Denmark and Spain, and was
lower in Poland and Norway.
Similar results were observed for pneumococcal meningitis,
with amean annual incidence of 10.7 (active surveillance) and 10.2
(passive surveillance) for children aged <2 years compared with
5.4 (active surveillance) and 6.3 (passive surveillance) for children
aged <5 years. Figure 2 shows the annual incidence of
pneumococcal meningitis and related PCV7 coverage from studies
that employed active surveillance. The anticipatedmean incidence
of preventable disease corresponded to the mean incidence of
pneumococcal meningitis, with a higher rate for children aged <2
years (8.5 (active surveillance); 7.3 (passive surveillance))
compared with those aged <5 years (4.4 (active surveillance);
4.4 (passive surveillance)). Pneumococcal meningitis was less
prevalent in Italy (active), Slovakia (active), and Poland (passive),
and wasmore ubiquitous in Belgium (active), Denmark (active and
passive), the UK (active and passive), and Spain (passive).
Of note, the deﬁnitions of active surveillance differed among
some studies. These differences and the differences between the
active and passive surveillance methodologies likely contributed
to under-reporting of the incidence of pneumococcal disease in
many countries.73.1.1.2. Special/high-risk populations. The incidence of and/or risk
of developing IPD was higher in boys compared with girls in
Denmark, Greece, Norway, and the UK.36,37,41,54 Most of these
children were aged <5 years, as were children in Greece who had
an elevated incidence of pneumococcal meningitis compared with
older children.54 Studies in Denmark demonstrated the age-
speciﬁc incidence of IPD, where the greatest incidence appeared in
children aged <2 or <5 years and in the elderly.22,55 Children aged
1–2 years in day care in East Germany (15.8; 95% conﬁdence
interval (CI) 13.7–18.0) were shown to be at increased risk for IPD
(cases/100 000) compared with those inWest Germany (11.0; 95%
CI 10.3–11.7).25 Cochlear implants have been associated with high
risk for pneumococcal meningitis, in addition to surgery of the
middle or inner ears, malformation of the labyrinth, injury, and
cerebrospinal ﬂuid leaks.56–58 Studies demonstrated that children
aged <5 years with this condition could beneﬁt from vaccination
with PCV7 to help prevent pneumococcal meningitis.56,57,59,60
Underlying medical conditions for children with IPD in this
review from Europe included cerebrospinal ﬂuid leak (0.3–0.5%),
presence of cerebrospinal ﬂuid shunts (1.1%), congenital/chronic
cardiac disease (1.0–3.3%), chronic pulmonary disease (0.6–1.1%),
asthma (0.6–3.9%), nephrotic syndrome (1.3%), renal insufﬁciency
(0.3%), chronic renal failure (0.5–1.1%), asplenia (1.4–3.2%),
diabetes mellitus (0.2%), prematurity (3.9%), Down syndrome
(0.6%), sickle cell anemia (0.9%), immunodeﬁciency (1.5–4.5%), HIV
(0.6–1.0%), malignancy (1.5–13.4%), or immunosuppressive ther-
apy/chemotherapy (1.4%–3.1%).21,23,26,32,35,61 Incidence of IPD
(cases/100 000) in these studies ranged from 16 to 104.4 for
children aged <2 years, 3.9 to 59.5 for children aged <5 years, and
1.4 to 8.9 for children aged <16 years.
Underlying medical conditions for children with pneumococcal
meningitis included neurological deﬁcits prior to meningitis (9.3%),
recent neurosurgery (5.8%), previous episode of meningitis (4.7%),
head injury (4.7–33%), presence of cerebrospinal ﬂuid shunts (1.1%),
Table 1
Annual incidence of invasive pneumococcal disease and estimated incidence of preventable disease.
Country [Ref.] Age Mean incidence of IPDa Year PCV7 serotype coverage Incidence of preventable diseaseb
Active surveillance
Austria [20] <2 years 14.5 2001–2003 NR -
2–5 years 7.8 2001–2003 NR -
<5 years 13.7 2001–2003 69.6% 9.5
Belgium [21] <5 years 59.5 2002–2003c 67% 39.9
<2 years 104.4 2002–2003 75% 78.3
Denmark [22] <2 years 43d 1995–1999 71.7% 30.8
Finland [23] <2 years 45.3 1985–1989 84.7% 38.4
Germany [24] 2–4 years 3.3 1997–2003 73.0% 2.4
Germany [25]
West Germany 1–2 years 11.0 1997–2002 72% 7.9
East Germany 1–2 years 15.8 1997–2002 85% 13.4
Germany [26] <2 years 16.0 1997–1998 52%e 8.3
<5 years 8.9 1997–1998 52%e 4.6
Germany [27] <2 years 16.3 1997–2000 75%f 12.2
<5 years 8.9 1997–2000 72.3% 6.4
Hungary [28] 2 years 12.5 2002–2004 NR -
<5 years 14.9 2002–2004 60.6% 9.0
Italy [29] <2 years 11.3 2001–2002 72%g 8.1
<5 years 6.3 2001–2002 72% 4.5
Norway [30] <2 years 50.0 2000–2005 37% 18.5
Portugal [17] 1 year 11.5 1999–2001 70.1% 8.1
2–3 years 5.4 1999–2001 70.1% 3.8
4–5 years 3.1 1999–2001 70.1% 2.2
Slovakia [31] <5 years 4.0 2001–2003 77.3% 3.1
Spain [32] <2 years 32.4 1997–2001 83% 26.9
2–4 years 11.3 1997–2001 60% 6.8
Spain [33] 2 years 16.8 1996–1998 NR -
5 years 10.5 1996–1998 NR -
UK [35] <2 years 37.8 1980–1999 84%e 31.8
<5 years 20.0 1980–1999 84%e 16.8
UK [36] <1 year 48.1 1995–1999 75.4%g 36.3
<5 years 21.2 1995–1999 75.4% 16.0
Passive surveillance
Denmark [38] <2 years 50.9 2000–2005 64%g 32.6
<5 years 25.5 2000–2005 64% 16.3
Denmark [39] <2 years 62 1996–2007 63%e 39.1
Denmark [37] <1 year 39.4 1981–1999 82% 32.3
<2 years 34.9 1981–1999 64% 22.3
6 years 13.9 1981–1999 61% 8.5
Norway [41] <2 years 18.6 2001 72.7% 13.5
Poland [42] <2 years 19.0 2003–2004 73.1%g 13.9
2–5 years 5.8 2003–2004 73.1%g 4.2
5 years 17.6 2003–2004 73.1% 12.9
Slovenia [43] 0–1 year 56.9 1993–2001 73.7% 41.9
2–4 years 15.8 1993–2001 68.4% 10.8
Spain [44] <2 years 78.6 2000 75% 59.0
Spain [45] <2 years 48.4 1999–2001 70.4% 34.1
<5 years 34.5 1999–2001 66.6% 23.0
Spain [46] <2 years 93.5 1998–2001 79% 73.9
<5 years 56.1 1998–2001 75% 42.1
Spain [18] <1 year 110.2 1998–2001 71%f 78.2
<2 years 93.5 1998–2001 71%f 66.4
<5 years 56.2 1998–2001 71% 39.9
Spain [47] 5 years 96.9 1999–2001 70% 67.8
UK [49] 1 year 38.7 2000–2004 88.9% 34.4
2–4 years 4.7 2000–2004 71.0% 3.3
<5 years NR 2000–2004 76.5% -
UK [50] <2 years 17.2 1995–1997 69.8% 12.0
UK [51] 1 year 50d 1999–2001 86.4%g 43.2
2–4 years 14d 1999–2001 86.4%g 12.1
UK [19] 6–11 months 35.8 1996–1998 77% 27.6
12–17 months 33.9 1996–1998 84% 28.5
18–23 months 13.9 1996–1998 84% 11.7
2–4 years 8.1 1996–1998 67% 5.4
4–5 years 5.5 1996–1998 67% 3.7
UK [53] <5 years 22.8 1996–2005c 73% 16.6
IPD, invasive pneumococcal disease; NR=not reported; PCV7=7-valent pneumococcal conjugate vaccine.
a Reported incidence per 100 000 population/year.
b Calculated as total IPD incidencePCV7 serotype coverage, assuming a vaccine efﬁcacy of 100%.
c PCV7 use for at-risk patients.
d Estimated from a graph.
e PCV7 coverage for all children aged <16 years.
f PCV7 coverage for all children at 1 year of age.
g PCV7 coverage for all children aged <5 years.
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Figure 3. Mortality due to invasive pneumococcal disease.
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(7.7%), extremeprematurity (33%), or congenitalmalformation (4.7–
33%).35,48 Incidence of pneumococcal meningitis (cases/100 000) in
these studies ranged from10.0 to37.8 forchildrenaged<2yearsand
5.8 to 20.0 for children aged <5 years.
3.1.1.3. Mortality. Figure 3 presents mortality rates due to
pneumococcal disease available from Austria, Belgium, Denmark,
Finland, France, Germany, Greece, Hungary, Italy, Poland, Slovakia,
Spain, Sweden, Turkey, and the UK.19–21,23,26-29,31–33,35,38,39,42,
44,45,48,51,52,54,61–66 Case fatality rates (CFR) for IPD in children aged
<5 years ranged from 0.7% in Poland42 to 36.4% in Slovakia,31 with
a mean CFR of 7.4%. For children aged <2 years, the CFR for IPD
ranged from 0.9% in France62 to 8% in Italy,29 with a mean of 3.5%.
CFRs for pneumococcal meningitis in children aged <5 years
ranged from 1.1% in the UK19 to 36.4% in Slovakia,31 and for
children aged<2 years ranged from 1.1% to 7.1% in the UK.19,52 The
mean CFRs for pneumococcal meningitis were 11.4% and 4.1% for
children aged <5 and <2 years, respectively. Generally, a
discordance between the incidence rate and the CFR, as seen in
the UK study,52 suggests that only the most severe cases were
captured by the given surveillance system. The broad range of CFRs
may be related to differences in the patient populations captured
by the various surveillance systems, and, to a lesser extent, the
differences in healthcare among the countries.
3.1.1.4. General antibiotic susceptibility trends. The distribution of
antibiotic-resistant pneumococci in Europe differs geographically,with higher rates of resistance in France, Spain, and Eastern
European countries compared with Germany and Northern
European countries.67 For the studies that included patients aged
<18 years, approximately 31% of the pneumococcal isolates were
penicillin G non-susceptible (range 0% in Sweden and Finland to
52% in Spain),23,34,45,48,68,69 26% were erythromycin-resistant
(range 3% in Finland to 48% in France),23,70 and 10% were resistant
to the third-generation cephalosporins ceftriaxone or cefotaxime
(range 0% in Finland and Germany to 27% in Spain).23,26,44
Table 2 summarizes available information in young children
concerning the resistance of isolates to penicillin G, erythromycin,
and third-generation cephalosporins by country. The proportion of
isolates with penicillin G non-susceptibility, including intermediate
andhigh-level resistance, for children aged<5 years ranged from5%
inDenmark37 to 55% in Slovakia,31with amean of 29%.Data from11
studies showed 5% of isolates with high-level penicillin resistance
and 23% with intermediate resistance. For children aged <2 years,
the percentage of isolates showing penicillin G non-susceptibility
ranged from 0% in Finland23 to 48% in France,70 with a mean of 23%.
In Germany, a signiﬁcant amount of penicillin G resistance was
associated with serotype 19A, and also with 6A/C and 7F by 2004.71
ConsiderablepenicillinGresistancewasassociatedwithserotype14
in Poland;42 however, no signiﬁcant difference in penicillin G
resistance was observed in vaccine serotypes versus non-vaccine
serotypes in the UK in 2005.53 In France, the serogroups included in
PCV7 covered 90% of penicillin G non-susceptible strains from
bacteremic isolates from children aged <2 years.72
Erythromycin-resistant isolateswere observedmore frequently
among children than adults.73 For children aged <5 years, the
mean proportion of erythromycin-resistant isolates was 35%
(range 7% in Denmark37 to 53% in Spain47), and for children aged
<2 years the mean proportion of erythromycin-resistant isolates
was 41% (range 26% in Germany25 to 59% in Belgium21).
Erythromycin resistance was often associated with pneumococcal
serotype 14.25,37,42,53,73–75
Of 12 studies reporting antibiotic resistance to third-generation
cephalosporins in children aged5 years, approximately 9% of IPD
isolates were resistant to cefotaxime or ceftriaxone (range 0% in
Finland, France, and Italy, to 36% in Slovakia).23,31,70,76
3.1.2. IPD serotypes
3.1.2.1. Serotype coverage of PCV7. The incidence and serotype
distribution of IPD in Europe have been studied extensively and
have been summarized recently.5,6,67 PCV7 serotype coverage for
children aged <5 years in Europe ranges from 50% in Spain and
Sweden77,78 to 100% in Greece,79 with a mean of 71%; for children
aged <2 years, PCV7 serotype coverage ranges from 37% in
Norway30 to 100% in Greece,79 with amean of 72%. See Table 2 for a
summary of published reports on PCV7 coverage for pediatric
IPD.17–23,25,27–32,34–38,40–47,49–51,53,61,62,65,66,68,70,72–74,76–100
Throughout Europe themost common serotypes causing IPD are
14, 6B, 19F, and23F. Variation is seen throughoutEurope in serotype
distribution of IPD isolates based on age, geography, and disease.
There is a direct correlation between serotype variation and
increasing age. This was demonstrated in a report from Turkey101
in which a wide variation in serotype distribution was seen for IPD
isolates. Resulting serotype coverage for any conjugate pneumo-
coccal vaccine was less than 50%, probably due to a low number of
isolates, inclusion of bronchoalveolar lavage specimens in IPD
cases, and wide age range (up to 16 years).
Certain serotypes, particularly serotypes 1 and 5, are seenmore
frequently in older children (aged >2 or >5 years).102 Reports
from Spain,32,46,65,92,103 Belgium,81 Germany,27 and Sweden95
demonstrate this well. The median ages of patients with serotypes
1 and 5 infections were 5.5 years and 5.0 years compared with 0.8,
Table 2
Pneumococcal serotype coverage for PCV7 and investigational 10- and 13-valent PCVs against IPD and antibiotic susceptibility data in European children prior to
implementation of national immunization programs.
Country No. of isolates
analyzed for
serotype
Age Year Antibiotic
non-susceptibility (%)
Vaccine serotype/
serogroup coverage (%)
Ref.
P E C 7v 10v 13v
Austria 56 <5 years 2001–2003 21 34 20 70 74 80 20
Belgium 185a <2 years 2002–2003 15 59 NS 75 79 95 21
280a <5 years 2002–2003 14 35 NS 67 78 93
86b <5 years 1997–2000 17 NS NS 81 NS NS 80c
843d <5 years 1994–2000 14 48 NS 82 NS NS 74c
NSd <5 years 1994–2004 13 48 NS 82 NS 93 81c
Czech Republic 108 <2 years 1999–2000 NS NS NS 62 70 86 82
152 <2 years 1996–2003 NS NS NS 63 NS NS 83
168 2–5 years 1996–2003 NS NS NS 62 NS NS
Denmark 511 <5 years 2000–2005 NS NS NS 64 82 91 38
311 <2 years 1995–1999 11 NS NS 72 80 85 22
806 <2 years 1981–1999 NS NS NS 64 78 87 37
1123 6 years 1981–1999 0–5 7 NS 61 78 87
Finland 224 <2 years 1995–1999 NS NS NS 72 79 93 84
235 <2 years 1985–1989 0 NS 0 85 NS NS 23c
France 252b <2 years 2001–2003 NS NS NS 65 NS NS 62
41 <2 years 1997–2002 48 NS 0 73 78 85 70
NSd <2 years 2001 NS NS NS 77 NS NS 72c
West Germany 334 1–2 years 1997–2002 NS 26 NS 72 NS NS 25
East Germany 89 1–2 years 1997–2002 NS 47 NS 85 NS NS 25
Germany NSb 6–71 months 1997–2000 NS NS NS 72 NS NS 27
Greece 103 2 years 2001–2004 NS NS NS 87 NS NS 85
39 <2 years 2000–2004 NS NS NS 100e NS NS 79
33 <2 years 2000–2002 NS NS NS 88 91 94 86
46 <5 years 2000–2004 NS NS NS 100e NS NS 79
51 <5 years 2000–2002 NS NS NS 76 88 92 86
Hungary 66 <5 years 2002–2004 33 47 3 61 NS NS 28
Italy 30d <2 years 2002–2003 NS NS NS 70 80 87 76
42d <5 years 2002–2003 21 43 0 67 79 88
14 <5 years 2001–2002 NS NS NS 71 78 93 29
51 <5 years 1997–2000 6 41 NS 73 88 100 73
25b 5 years 1996–1999 NS NS NS 80 NS NS 87
Netherlands NSb <5 years 1990–1999 NS NS NS 59 NS NS 40
Norway 291 <2 years 1999–2005 NS NS NS 37 NS 56 30
325 5 years 1995–2001 NS NS NS 62 79 88 41
NS <2 years 1995–2001 NS NS NS 73 NS NS
24 <5 years 1985–1990 NS NS NS 63 67 83 88
Poland 26 5 years 2003–2004 31 31 8 73 NS NS 42
15b <2 years 1997–2001 NS NS NS 60 67 73 89
Portugal 57 <2 years 1999–2002 NS NS NS 63 NS NS 90
82 5 years 1999–2002 44 21 1 60 77 89
67 1–5 years 1999–2001 NS NS NS 70 NS NS 17
Slovakia 22f <5 years 2001–2003 55 32 36 77 NS NS 31
Slovenia 91 <1 years 1993–2001 NS NS NS 74 78 89 43
104 2–4 years 1993–2001 NS NS NS 68 76 85
Spain 14g 2 years 1998–2004 NS NS NS 93 NS NS 91c
34 <2 years 1998–2003h NS NS NS 79 85 NS 46c
NSb <2 years 2000–2001 NS NS NS 80 NS NS 34
29 <2 years 1997–2001 NS NS NS 83 NS NS 32
NSd <2years 1994–2001 NS NS NS 60 NS NS 65
71 <2 years 1981–2001 NS NS NS 70 NS NS 45
NSd <2 years 1986–2000 NS NS NS 75 NS NS 44c
NS <2 years 1990–1999 NS NS NS 83 NS NS 92c
19d <3 years 2000–2001 NS NS NS 74 74 95 93
25 2–5 years 1998–2003h 48i NS NS 68 92 NS 46c
67 <5 years 2001–2002 NS NS NS 51 58 94 94
59 <5 years 1998–2001 48 NS 7 71 85 92 18
15 2–4 years 1997–2001 NS NS NS 60 NS NS 32
96 <5 years 1981–2001 NS NS NS 67 NS NS 45
58 <5 years 1999–2001 49 53 4 71 86 93 47
20b 5 years 1989–2000 49 27 20 50 60 80 77
NS 2–5 years 1990–1999 NS NS NS 63 NS NS 68c
Sweden 76 <2 years 1998–2001 NS NS NS 66 NS NS 95
26 <5 years 1998–2001 NS NS NS 50 77 92 78
Switzerland NSa,g <2 years 2001–2004 NS NS NS 65 NS NS 96
107a,g <5 years 2001–2004 NS NS NS 60 65 80
Turkey 27j <2 years 2001–2004 41 33 11 63 70 78 61
UK 99 1 year 2000–2004 NS NS NS 90 NS NS 97
99 1 year 2000–2004 NS NS NS 90 93 96 49
38 2–4 years 2000–2004 NS NS NS 71 76 92
217 <2 years 1988–1999 NS NS NS 84 90 NS 98c
717 <2 years 1996–1998 NS NS NS 70 NS NS 19c
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Table 2 (Continued )
Country No. of isolates
analyzed for
serotype
Age Year Antibiotic
non-susceptibility (%)
Vaccine serotype/
serogroup coverage (%)
Ref.
P E C 7v 10v 13v
769 <2 years 1995–1997 NS NS NS 70 78 91 50
341a <5 years 1996–2005 NS 21 NS 73 NS NS 53
217 <5 years 2000–2004 NS NS NS 76 81 91 49
217 <5 years 2000–2004 NS NS NS 77 NS NS 97
71 <5 years 2003 NS NS NS 72 76 85 99
169 <5 years 1999–2001 NS NS NS 86 89 92 51c
246 5 years 1988–1999 NS NS NS 82 90 NS 98c
138 <5 years 1995–1999 NS NS NS 75 83 96 36c
NS 6 months–5 years 1980–1999 NS NS NS 84 NS NS 35c
250 2–4 years 1996–1998 NS NS NS 67 NS NS 19c
80 <5 years 1991–1996 NS NS NS 92 NS NS 66c
576 5 years 1986–1990 NS NS NS 80 88 91 100c
PCV, pneumococcal conjugate vaccine; IPD, invasive pneumococcal disease; P, penicillin; E, erythromycin; C, cephalosporins (ceftriaxone or cefotaxime); 7v, 7-valent; 10v,
10-valent; 13v, 13-valent; NS, not stated.
a PCV7 use for at-risk patients.
b Meningitis only.
c Serogroup data were used for calculation of vaccine coverage.
d Bacteremia only.
e Serotype distribution included only 19F, 6B, 14, and 18C.
f Also included seven pneumococcal isolates from pneumonia (4), pneumonia-otitis (2), and otitis (1).
g ‘Low’ level PCV7 use.
h 28–37% of children received PCV7 from 2002 to 2003.
i <5 years 48% during 1998–2001 then 20% by 2003.
j Also included 12 pneumococcal isolates from pneumonia.
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18C, respectively.65 Spanish data from 1990 to 1999 demonstrated
that 19.4% of invasive isolates in children 5 to 14 years of age were
serotype 1. This decreased to 16.1% for those aged 2 to 5 years, and
was very infrequent (1.8%) in children aged<2 years.92 In Sweden,
serotype 1 was the most common serotype in children aged >2
years, but was not found in those aged <2 years.95 Serotype 1 was
also more likely to be seen in older children and in complicated
pneumonia syndromes in Spain, where serotype 1 caused 21% of
bacteremic pneumonias in children aged <15 years but only 4% in
those aged <59 months.103 In addition to serotype 1, a consider-
able proportion of complicated pneumonia isolates in Spain were
serotypes 3 and 5.102 Serotype 1 has also been associated with
childhood empyema in the UK.104,105
PCV7 coverage of meningitis also varies by age, as seen in the
Netherlands where coverage was 59% for children aged <5 years40
but 68% for those aged<2 years.106 This was also observed in parts
of Spain where PCV7 coverage for meningitis was 64% for those
aged <14 years but increased to 80% for children aged <2 years,34
and in the UK52 where PCV7 coverage for children aged 2 to 5
monthswas approximately 53% and for those aged 1 to 2 yearswas
approximately 84%.
Variation is also noted over time, exempliﬁed by a report from
the UK that compared serotypes from IPD isolates of children aged
<16 years from 1980–1989 to those of 1990–1999. PCV7 coverage
increased from 65% to 75%. This changewas primarily attributed to
an increase in serotype 14.35
Serotype variation between countries is seen most frequently
for serotypes 1, 3, and 5. In Norway and Sweden, serotype 1 has
declined in frequency in recent years.41,95 Serotype 3 was found in
13% of young children with IPD in Switzerland96 and in 7.4% in the
Czech Republic,82 although it was less common in young children
in other European countries. Individual disease coverage rates also
ﬂuctuate by country. For example, PCV7 coverage rates for
meningitis vary from 50% to >85%.28,34,40,52,62,73,106
3.1.2.2. Serotype by clinical manifestation. From this review, the
serotypes/serogroups most often associated with pediatric (<18
years) pneumococcal meningitis were 14 (18%), 19 (18%), 6B (17%),23F (15%), and 18C (15%). In the studies that reportedmeningitis in
patients aged <5 years only, the distribution of serotypes/
serogroups was similar, i.e., 14 (19%), 6B (19%), 23F (17%), and
19 (13%),37,61,62,77,80,87,89 although the percentages of serotypes 6B
(31%) and 7F (15%) were somewhat higher in children in
Denmark.38
For bacteremia in patients aged <18 years, the most common
pneumococcal serotypes/serogroups isolated were 14 (23%), 1
(23%), 6B (19%), 23F (17%), and 19 (13%). In studies reporting on
bacteremia in children <5 years of age, serotype 14 was the
predominant serotype.37,74,76
3.1.2.3. Serotype coverage of investigational PCV10 and PCV13. O-
verall, vaccine serotype coverage ranged from 67% to 93% for
investigational 10-valent PCV and from 56% to 95% for investiga-
tional 13-valent PCV, providing average increments of additional
coverage of 7% and 16% over PCV7, respectively, for European
children in the target age group of <2 years (Table 2).
Two studies were performed in different regions of Spain in
children aged <59 months. In one study, the investigational 10-
valent PCV would increase serotype coverage by 12% from that
of PCV7 due to the presence of serotypes 1 and 5.103 In the other
study, the investigational 13-valent PCV would increase cover-
age from PCV7 by 17% due to serotypes 1, 3, 5 and 7F.46 In
Sweden, incremental serotype coverages for isolates in older
children (aged 18 years) would be increased 30% with
investigational 10-valent PCV and 38% with investigational
13-valent PCV due to serotypes 1 and 7F.95 For children aged <5
years, investigational 10-valent PCV would potentially increase
coverage by 27% and investigational 13-valent PCV would
increase coverage over PCV7 by 42% due to serotypes 1, 6A/C, 7F,
and 19A.78 Compared with PCV7, the investigational 13-valent
PCV would increase serotype coverage by 19% for children aged
<5 years in Switzerland96 and 24% for children aged <2 years in
the Czech Republic82 mostly due to serotype 3. In the UK,
incremental serotype coverages for isolates in children aged 1
year would be increased 5% with investigational 10-valent PCV
and 15% with investigational 13-valent PCV due to serotypes 1,
3, 6A/C, and 19A.49
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Although PCV7 was ofﬁcially licensed in Europe in 2001, it was
only used in some countries and under speciﬁc conditions, such as
in high-risk patients.16 The implementation of PCV7 in national
immunization programs in European countries is shown in Table 3
along with the recommended treatment schedules used by each
country and the plans for ‘catch-up’ immunizations (on ﬁle at
Wyeth Pharmaceuticals, USA). Although PCV7 was originally
licensed for use in a four-dose regimen (i.e., three primary
immunizations and a booster dose (3 + 1)), a three-dose schedule
(i.e., two primary immunizations and a booster dose (2 + 1)), is
used in some countries.107–110 For cost-effectiveness, PCV7
vaccinations can be administered at the time of other childhood
vaccinations. The following compares available data from children
before and after widespread PCV7 immunization, with Figure 4
highlighting differences in IPD incidence, PCV7 coverage, and
antibiotic non-susceptibility.
3.2.1. Epidemiology following widespread immunization with PCV7
3.2.1.1. Incidence of IPD, clinical manifestations, and special/high-
risk populations followingwidespread immunizationwith PCV7. Re-
sults regarding the impact of PCV7 on IPD in children are
documented in France, Germany, Spain, the UK, Portugal, and
Norway.17,32,46,47,63,93,107,110–122
Children aged <2 years demonstrated signiﬁcant declines
in bacteremia and meningitis in France.123 Reductions of 39% in
pneumococcal meningitis and 29% in bacteremia were observed in
2005, compared with the pre-vaccine period (1998–2002)
(p < 0.001). Another study showed that pneumococcal meningitis
cases decreased by 28% (p < 0.05) in 2005, with approximately 50%
complete vaccine uptake noted.63 There was no reduction in total
cases in children with underlying conditions predisposing them to
pneumococcal meningitis before (n = 16) and after (n = 18)
implementation of the national immunization program versus
those without underlying conditions.63
In Germany, IPD cases due to vaccine serotypes in children aged
<2 years were reduced by 50% in 2008; non-vaccine serotype cases
were similar to previous years.112 A smaller reduction was
observed in the group aged 24 to 59 months that could be
attributed to either ‘catch-up’ immunization or indirect immunity.
The vaccine uptake rate was approximately 84% for children aged
<2 years.
Several studies in Spain also provide data regarding the effect of
PCV7 on the incidence of IPD in young children. In Basque Country
and Navarre, where vaccine uptake was 28% to 45%, the incidence
of IPD (cases/100 000) in children aged<2 years was reduced from
93.5 in 1998–2001 to 56.3 in 2003, a 40% decrease in incidence
(p < 0.05).46 Similar reductions were observed for children aged
<1 year (64% decline; p < 0.01) and for children aged <5 years
(38% decline; p < 0.01). Speciﬁcally, the incidence of pneumococ-
cal bacteremiawas reduced (58%; p < 0.01), aswas the incidence of
pneumococcal meningitis (p < 0.05) among children aged <5
years.46 In Barcelona, the overall incidence of IPD in children aged
5 years decreased from 96.9 to 90.6 from 1999 to 2004.47 With
approximately a third of the eligible children having received PCV7
during the vaccine period, pneumococcal meningitis (cases/100
000) was reduced by 68% (3.4 to 1.4) and bacteremia decreased
from 59.4 to 49.8; however, the incidence of empyema increased
(1.7 to 8.5). Another study in Barcelona demonstrated a 58%
increase (p = 0.037) in the overall incidence of IPD among children
aged <2 years (32.4 to 51.3 from 1997 to 2006).32 Since there was
little change in the incidence of meningitis and bacteremia, the
elevated IPD rate occurred mostly as a result of the increased
incidence of empyema (2.2 to 9.2; p = 0.055). The increase inempyema was probably due to circulating serotypes 1 and 5 prior
to vaccine implementation.33 The authors did not suggest a causal
association between the vaccine and the emergence of non-vaccine
serotype empyema.
Weekly numbers of IPD cases in the UK due to vaccine serotypes
were shown to decline by approximately 250, whereas those
caused by non-vaccine serotypes increased by approximately 100
in children aged <2 years after PCV7 immunization.124
Overall, the uptake of PCV7 ranged from 28% in Spain46 to 95%
in Norway.107 After widespread PCV7 vaccination, there was a
mean decline in the incidence of IPD in children aged<2 years from
32.5 to 23.4/100 000.32,46,107,108 In two additional studies that did
not report incidence rates, a 39% mean decrease in IPD was noted
after widespread PCV7 use.63,113 A large variation in effectiveness
is apparent, based on vaccine uptake and reporting methods.
3.2.1.2. General antibiotic susceptibility trends following widespread
immunization with PCV7. Overall, four studies provided data
describing the impact of PCV7 on antibiotic susceptibility in
children aged <5 years. Mean penicillin non-susceptibility was
reduced from 48% to 29%, macrolide non-susceptibility was
reduced from 43% to 26%, and cephalosporin non-susceptibility
was reduced by 10%.46,47,107,122
Following the initial licensure of PCV7 in the USA, the rates of
IPD caused by penicillin and erythromycin non-susceptible S.
pneumoniae declined by 81% and 80%, respectively, in children
aged <2 years.126 Penicillin non-susceptible serotype 19A
increased in frequency from 2% to 35% after PCV7 use; vaccine
uptake at the time was estimated at 73%.125
There was a signiﬁcant decline in penicillin non-susceptibility
after PCV7 vaccination in two studies from Spain: one included
isolates from children aged <5 years (high-level resistance not
reported)46 and the other included isolates from older children
(high-level resistancewas reduced from 17% to 6% in children aged
<18 years).32 Erythromycin resistance was reduced in isolates
from children aged 5 years47 and from isolates in children aged
<18 years32 in Spain after PCV7 immunization. During the PCV7
vaccination years, cefotaxime resistance decreased in isolates from
children aged <5 years46 and from older children.32
Although PCV7 is not included in the national immunization
program in Portugal, it is recommended for all children aged <2
years and for those at risk of IPD on a voluntary basis. In Portugal,
children aged5 years had a signiﬁcant decrease in penicillin non-
susceptibility (45% of isolates in 1999–2002 versus 27% in 2003–
2005; p = 0.013).122 Older children who were vaccinated with
PCV7 had a signiﬁcant decrease in penicillin non-susceptibility
associated with a decline in serotypes 14, 6B, and 9 V counter-
balancing the increase in 19A.17 Ceftriaxone non-susceptibility
decreased with no associated change in serotypes. There was no
change in erythromycin resistance, but an increase in serotype
19A.
Macrolide resistance decreased in Norway after routine PCV7
vaccination of children aged <5 years (33% of isolates in 2005
versus 15% in 2007). The corresponding incidence of macrolide-
resistant IPD (cases/100 000) fell from 8.8 to 2.8 (p < 0.01).107
Resistance in France was only reported in older children (aged<16
years). In this age group, the proportion of penicillin-resistant
strains remained stable (11% in 2001 versus 13% in 2005).63 High-
level resistance was also similar pre- and post-PCV7 vaccination in
children in Greece (3% versus 4%).126
Antibiotic consumption is considered a major factor in
resistance. In 2004, the consumption of antibiotics in the USA
was ranked fourth compared with the European countries, with
France ranked second.127 In a French study where antibiotic
consumptionwas reduced bymore than 20% concurrentwith PCV7
immunization, children aged <2 years demonstrated a marked
Table 3
National immunization program status for PCV7 in Europe.
Country Date
implemented
Recommended
schedule
Catch-up details
Belgium Jan 2007 2+1 Until 23 months of age
Cyprus Aug 2008 3+1 None
Denmark Dec 2007 2+1 Until 18 months of age
France Oct 2008a 2+1a All children up to 23 months of age and identiﬁed risk groups up to 59 months of age
Germany Jul 2006 3+1 All children up to 23 months of age and identiﬁed risk groups up to 59 months of age
Greece Jan 2006 3+1 None
Hungary Apr 2008 2+1b None
Ireland Sep 2008 2+1 Until 23 months of age
Italy Dec 2006 2+1 None
Liechtenstein Jul 2006 2+1 Until 23 months of age
Luxembourg Feb 2003 3+1 None
Netherlands Jun 2006 3+1 None
Norway Jul 2006 2+1 Children 3–6 months
Slovak Republic Apr 2008c 2+1 None
Spain (Madrid regional program) Jan 2007 3+1d None
Switzerland Jul 2006 2+1 Until 23 months of age
Turkey Jul 2008 3+1 Until 23 months of age
UK Sep 2006 2+1 All children up to 23 months of age and identiﬁed risk groups up to 59 months of age
3+1= three primary immunizations followed by one booster immunization; 2 +1= two primary immunizations followed by one booster immunization.
a Started using 3+1 schedule in March 2003 as part of national immunization program, but changed to 2+1 schedule in October 2008.
b Was using 3+1 schedule, but changed to 2+1 schedule once national immunization program started.
c Recommended vaccine reimbursed at 97% for all children, but not listed as mandatory.
d Not fully established, 70% coverage.
Figure 4. Pre- and post-national immunization program (NIP) invasive
pneumococcal disease (IPD) incidence, 7-valent pneumococcal conjugate vaccine
(PCV7) coverage, and antibiotic non-susceptibility.
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This has implications for IPD since the portal of entry for most
invasive disease is the upper respiratory tract.
3.2.2. IPD serotypes following widespread immunization with PCV7
3.2.2.1. Serotype coverage following widespread immunization with
PCV7. The implementation of PCV7 into national immunization
programswill result in a signiﬁcant reduction in coverage since the
vaccine is designed to prevent invasive disease caused by vaccine
serotypes.
In France, a signiﬁcant decline in PCV7 serotypes was observed
from 2001 to 2005 (68% to 42%; p < 0.05) with a corresponding
increase in non-vaccine serotypes (16% to 31%; p < 0.05) and
related vaccine serotypes (16% to 27%; p < 0.05) in children aged
<2 years.63 No particular non-vaccine serotype emerged during
the study period.
In the Basque Country and Navarre, Spain study, incidence of
disease (cases/100 000) caused by vaccine serotypes was reduced
from 74.1 to 49.5 following uptake of PCV7, while the rate of
disease caused by non-vaccine serotypes remained unchanged in
children aged <2 years.46 The prevalent serogroups before PCV7
and during vaccine surveillance remained unchanged (i.e., 19, 6,
and 14). In another study in Basque Country, PCV7 reduced the rate
of bacteremia in children aged <3 years by 57.5% (p < 0.05); the
rate of bacteremia caused by PCV7 serotypes decreased by 79%
(p < 0.01), and the rate of bacteremia caused by non-vaccine
serotypes was unaffected (0.42% to 0.44%) from 2000 to 2005.92
Prevalent serotypes (in rank order) before PCV7 were 6B, 14, and
19A, and during vaccine surveillance were 19A, 19F, and 14. PCV7
coverage of IPD after widespread vaccination was 36%. Among
children aged <5 years in Navarre, IPD cases due to non-PCV7
serogroups increased from 2001 (9%) to 2005 (43%) (p = 0.02).94
Predominant serotypes in this studywere 19A, 19F, 14, 1, 6A/C, and
3; PCV7 coveragewas 41%. In Barcelona, an increase in non-vaccine
IPD serotypes was observed for children aged 5 years from the
pre-vaccine years (21%; 1999–2000) to the vaccine surveillance
years (44%; 2002–2004) (p = 0.01).47 The largest increases were
noted for serotypes 1 and 6A/C; PCV7 coverage was 46%. For
children aged<2 years in Barcelona, the incidence of IPD caused by
non-vaccine serotypes increased from 5.6 to 35.2 from 1997 to
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observed, as was an increase in the prevalence of serotypes 19A
and 6A/C expressing different clonal types during the vaccine
period.
In Portugal, a decline in the prevalence of vaccine serotypeswas
signiﬁcant (p = 0.01) for children aged <6 years after PCV7
vaccination in 2004. Non-vaccine serotypes 19A, 7F, and 33F
increased (p = 0.04); 6A/C became more common, but not
signiﬁcantly.17 Another study noted signiﬁcantly reduced vaccine
serotypes 6B, 14, and 23F (conditional relative risk (cRR) = 0.12,
0.26, 0.39, respectively) and increased non-vaccine serotype 19A
(cRR = 4.25) for children aged 5 years after PCV7 vaccination in
2005.122 In addition, indirect (herd) immunity was demonstrated
in adults with regard to pneumococcal serotype distribution of
invasive disease.122 Vaccine uptake was 43% in this study.
In Germany, the percentage of isolates of serotype 19A, as well
as the levels of penicillin and macrolide resistance, have remained
steady after the implementation of a national immunization
program.129
Estimation of the impact of PCV7 in theUKwas performed using
serotype coverage, vaccine efﬁcacy, and uptake to determine
potential reduction of IPD.75 In Scotland, PCV7 uptake was 91%.130
Accounting for PCV7 serotype coverage, vaccine efﬁcacy, and
uptake, reductions of 82% and 67% in all IPD cases are predicted for
children 1 year of age and for children between 2 months and <5
years of age, respectively, when PCV7 is fully implemented in the
UK.49 These approximations are comparable to the 69% decline in
IPD rates observed in the USA from 1998 to 2001 in children aged
<2 years (78% for disease caused by PCV7 serotypes and 50% for
vaccine-related serotypes).131 A reduction in disease rates also
occurred in adults (8–32%) during the same time period in the USA,
and more recent evidence has conﬁrmed the indirect or herd
immunity of PCV7.104,132 By 2007, the incidence of vaccine-type
IPD in children aged <5 years in the USA was reduced by 99%, and
the rate of vaccine-type IPD in adults declined by 87–92%.133 This
suggests improved herd protection. Additionally, data from the UK
estimated that 1168 deaths (98% adults) and 7147 cases (25%
adults) of serious pneumococcal infections would be prevented
from pediatric vaccination with PCV7.104
Results from a quantitative herd immunitymodel study done in
the USA indicated that PCV7 use in young children signiﬁcantly
reduced vaccine-type IPD in unvaccinated older children and
adults.134 The estimated reduction in IPD caused by PCV7
serotypes was directly correlated to the number of doses that
the children received, in that declines of 38%, 62%, and 77% were
predicted for one, two, and three, doses, respectively. However,
there is no cross-protection for serotype 19A and only partial cross-
protection for 6A/C;10 therefore, herd immunity does not occur for
these serotypes. Thus, serotypes 19A and 6A/C would need to be
included in future vaccine formulations.133 For optimal coverage in
most European countries, other serotypes, including 1, 3, 5, and 7F,
would also be beneﬁcial.
3.2.2.2. Serotype coverage of investigational PCV10 and PCV13
following widespread immunization with PCV7. Similar to the
reduction in PCV7 coverage following widespread immunization
with PCV7, a decline in coverage by investigational 10- and 13-
valent PCVs would be expected as they prevent invasive diseases
caused by vaccine serotypes.
One study from France, one study from Germany, and three
studies from Spain provided information to estimate the serotype
coverages of investigational 10- and 13-valent PCVs based on
children who have received PCV7 vaccinations. For children aged
<2 years in France, serotype coverages pre- and post-PCV7 for
investigational 10-valent PCV were 65% and 51%, respectively, and
coverages for 13-valent PCV were 86% and 76%, respectively.63 InGermany, investigational 10-valent PCV coverage for children aged
<2 years pre- and post-PCV7 immunization were 74% and 57%,
respectively, and investigational 13-valent PCV coverage was 80%
and 76–80%, respectively.112,113 In Barcelona, investigational 10-
and 13-valent PCV coverages in children aged 5 years were 69%
and 78%, respectively, due to increases in serotypes 1 and 6A/C.47
From a study in Navarre, Spain, that included 18 vaccinated and 67
unvaccinated children aged <5 years, the investigational 10- and
13-valent PCV coverages were 52% and 87%, respectively.94
Another study was comprised of children aged <3 years with
bacteremia from the Basque Country. Investigational 10-valent
PCV coverage was 36% and investigational 13-valent PCV coverage
was 82%.93 As noted previously, the prevalence of PCV7 serotypes
has markedly declined with the administration of PCV7. Thus, the
coverage of investigational 10- and 13-valent PCV is increasingly
represented by non-vaccine serotypes.
3.3. Limitations
There are some limitations to this review. First, only published
data are presented, which provides limited information with the
highest burden of pneumococcal disease. Second, because of
differences in methods used, data from studies performed in
different geographic locations are often difﬁcult to compare. Third,
many studies consisted of a passive laboratory-based system that
may represent the most severe or easily diagnosed cases. Active,
laboratory-based surveillance systems that include serotyping and
susceptibility testing would likely provide more representative
data.21 In addition, speciﬁc serotype coverage for PCV7 and the
investigational 10- and 13-valent PCVs could not always be
analyzed because only serogroup data were provided. This could
lead to an over-estimation of coverage for PCV7 and investigational
10-valent PCV due to the inclusion of serotypes 6A/C and 19A in the
calculations. When serotype data were available, coverage for the
different vaccines was estimated without consideration of cross-
protection, which we know is partial for serotype 6A/C, thus
potentially under-estimating PCV7 coverage and coverage for the
investigational 10-valent PCV if cross-protection is demonstrated.
It has been suggested that serotype 6A, which is included in the 13-
valent PCV, provides some cross-protection for serotype 6C in
children aged <5 years.135 If this cross-protection is insufﬁcient,
inclusion of serotype 6C in future vaccines may be a consideration.
Finally, bias could be introduced into the serotype coverage
calculations because of unknown vaccine uptake due to ‘at risk’
recommendations in different countries, i.e., more children could
have received PCV7 than were reported in the studies.
4. Conclusions
There is great variation in the overall burden of IPD in Europe,
which may in part result from differences in the deﬁnitions of IPD,
antibiotic prescribing methods, blood culturing practices, and
surveillance methods among different geographical areas. In
addition, the subtle onset of IPD, reluctance to perform lumbar
puncture, and under-reporting can all contribute to the dispar-
ity.5,6,67 The highest age-associated incidence of IPD occurs in
children aged<2 years. Reduction of IPD via vaccinationwith PCV7
has now been noted in several European countries, as has the
added beneﬁt of decreased frequency of antimicrobial resistant
pneumococci. Serotype coverage of the currently licensed hepta-
valent vaccine and the investigational 10- and 13-valent PCVs is an
important variable to assess potential vaccine impact.
In countries with routine effective use of PCV7, the proportion
of current coverage by PCV7 is lower than in the pre-vaccine era.
Use of PCV7was associatedwith a general decline in IPD, antibiotic
non-susceptibility, and vaccine serotypes. However, the incidence
D.J. Isaacman et al. / International Journal of Infectious Diseases 14 (2010) e197–e209 e207of serotypes 1, 19A, 3, 6A/C, and 7F increased, highlighting the need
for inclusion of these serotypes in future vaccine formulations.
In summary, data on the burden of IPD and the impact of PCV7
have illustrated the important role this vaccine has played in
disease prevention in Europe. Inclusion of additional serotypes,
including serotypes 1, 3, 5, 6A/C, 7F, and 19A, would be warranted
in future investigational vaccine formulations.
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